




Can Keep Them “Happy For Life”

By Treating The Root Causes of Depression



Indication:
**Clinical Dietary Management
of Major Depressive Disorder**

Once-a-day dosing / No age restriction

Team Methylation

Pre-metabolized Coenzymes &
Cofactors: **Brain Ready Ingredients**



Reduced Folates

L-Methylfolate Magnesium	7mg
Folinic Acid (Leucovorin)	3.5mg

B Vitamins in their Bioactive Coenzyme Form

B12 (Adenosylcobalamin)	50mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
Bioperine (B Vitamin Bioenhancer)	500mcg
Betaine (Trimethyl Glycine)	1mg

Minerals in their Bioactive Cofactor Form

Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Zinc Ascorbate	1mg
Ferrous Glycine Cysteinate	1.5mg

Phospholipid Form—Brain Ready

PS-Omega-3 (Phosphatidylserine, EPA, DHA)	23.3mg
---	--------

Absorption Enhancer

Sodium Citrate	6mg
----------------	-----

Energizer

CoQ10	500mcg
-------	--------


CNS Biochemical Actions:

1. Normalizes and balances neurotransmitter production (serotonin, dopamine, norepinephrine, epinephrine and GABA)
2. Normalizes production of endogenous SAM-E for methylation of DNA, RNA, proteins and lipids
3. Normalizes glutathione production
4. Reduces high homocysteine

METHYLATION CHART

EnLyte/EnBrace HR provides all the downstream coenzymes, cofactors, and omegas needed to normalize and balance biochemical endpoints which correlates into clinical remissions in well-controlled clinical trials.

EnLyte, EnBrace HR Product Ingredients **Maroon** | Biochemical End Points **Green**



THE JOURNAL OF CLINICAL PSYCHIATRY

MAY 2016



Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR
in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism

Andrew Farah, MD

330

**ADULT PATIENT RANDOMIZED DOUBLE
BLIND PLACEBO CONTROLLED STUDY**

OBJECTIVE: This study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.




NO SIDE EFFECT WAS REPORTED AT GREATER RATE THAN PLACEBO

ONSET OF ACTION 2 WEEKS

Results

Figure 1. Mood and Quality of Life Outcomes

Group 1 – Relapse Prevention Group; Well at Baseline



Group 2 – Acute Treatment Group; Depressed at Baseline




Figure 1. The aim for Group 1 was to prevent depression relapse, and the aim for Group 2 was to improve depression symptoms, measured through several mood and quality of life questionnaires. Trends shown by group for the primary mood outcome measure, the MADRS (Montgomery-Asberg Depression Rating Scale) in dark blue; for secondary mood measures, the QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report) in orange and the EPDS (Edinburgh Postnatal Depression Scale) in light blue; and for a quality of life outcome, the QLESQ-SF (Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form) in green. Group 1 experienced no significant changes in any of the four measures, and Group 2 experienced significant improvements in the mood questionnaires but not the quality of life questionnaire. All ANOVAs indicating significance are reported in Table 3.

Conclusion:

- Study results suggest EnBrace HR is a novel and well tolerated intervention with efficacy for the prevention and treatment of depression among women planning pregnancy and who are pregnant.

EnLyte and EnBrace HR are indicated as monotherapy or adjunctive therapy as determined by a licensed medical practitioner.

ADJUNCTIVE THERAPY

- Combine with SSRIs or SNRIs from the start to enhance results, reduce dropout rates and for non-responsive patients.
- Augmentation can precede atypical antipsychotic augmentation therapy

APA Guidelines for MDD state: “...Considering the modest evidence that supports folate as an augmentation strategy and its attractive risk-benefit profile, folate can be recommended as a reasonable adjunctive strategy for major depressive disorder that carries little risk...”

MONOTHERAPY PATIENT

- MTHFR Positive
- MTHFR Suspected Based on Family History of:
 - Mental Illness
 - Addiction
 - Diabetes
 - Miscarriages or Birth Defects
 - Cardiovascular Issues
- Folate depleted based on folate depleting conditions, drugs and population
- To avoid potential side effects of antidepressants
- Before, during and after pregnancy (Pregnancy Category A)
- Addiction Support

CONTRIBUTORS TO FOLATE DEFICIENCY

CONDITIONS	DRUGS	POPULATION
Malabsorption Syndromes	Lamictal	United States: 75% have a form of MTHFR SNP
Digestive Tract Disease	Metformin	
Pregnancy	Methotrexate	
Breast Feeding	Corticosteroids	HIGHER RISK
Kidney Disease	NSAIDs	Hispanic
Liver Disease	Antibiotics	Mediterranean
Cancer	Anticonvulsants	Chinese
Canker Sores	Oral Contraceptives	African American
Alcohol or Drug Abuse	Cholesterol Lowering	
Smoking	Diuretics	
Anemias	H2 Antagonists	
Overcooked Foods		

PATIENTS CAN FEEL COMPLETELY SAFE

Possible Side Effects	EnLyte	SSRI's	SNRI's
Weight Gain	No!	Yes	Yes
Loss of Libido, difficulty achieving erections, inability to reach orgasm	No!	Yes	Yes
Increased thoughts of suicide and aggression in adolescents & adults	No!	Yes	Yes
Drowsiness or Confusion	No!	Yes	Yes
Nervousness & Agitation	No!	Yes	Yes

Phone: 985-629-5825

Website: www.Enlyterx.com

**We are here to help!
Please call with any questions.**

HOW TO PRESCRIBE

STEP 1

SUBMIT OUR ELECTRONIC FORM

Visit www.enlyterx.com

- Click "Prescribe Now"
- Fill out the required information
- Click "Submit."

**EnLyte and EnBrace HR will be available in your EMR, but the most cost-effective way to prescribe is by using the "Prescribe Now" button. This ensures your patients receive 60 days for just \$60, and the lowest price available moving forward.*

STEP 2

INFORM YOUR PATIENT

Let your patient know that a friendly customer care representative will contact them shortly to get started on EnLyte for just \$1 a day for the first 60 days.

STEP 3

WE TAKE CARE OF THE REST

A representative will contact your patient to arrange the initial **60-day trial for just \$60**, which will typically be shipped the same day.

REFILLS:

Our Medical Food Distributor will handle all refills to ensure uninterrupted care.



Natural + Safe + Proven

**TRUSTED BY
MEDICAL
PROVIDERS
NATIONWIDE**

What is EnLyte (ENL)?

EnLyte (ENL) is a small gel cap containing all the brain-ready micronutrients needed to normalize and balance brain chemicals that regulate mood.



People first notice improved energy, focus, concentration & sleep and most begin to feel a difference in about 2 weeks."

Andrew Farah, MD



www.enlyterx.com

Clinically Proven

In one of EnLyte's important published clinical trials, participants with Major Depressive Disorder saw a 75% improvement and 42% remission compared to placebo*.

*Published in the Journal of Clinical Psychiatry, 2016

EnLyte Helps with:

- MTHFR Genetic Issues
- Depressed Mood
- Apathy/Loss of interest
- Anxiety/Worry
- Irritability
- Problems Concentrating
- Sleep

Safe Ingredients

EnLyte contains natural ingredients that are generally recognized as safe by the FDA and are gluten-free, dairy-free, wheat-free, sugar-free, egg-free, with no artificial colorants.

Dosing

The recommended dosing is (1) gel cap in the morning, when you wake up (on an empty stomach) or as recommended by your healthcare provider. ENL has No age restriction.



To Order and For a Full List of Ingredients visit:

www.enlyterx.com



985-629-5825